Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?
Are the experts convinced by DFS when the OS is immature?
How many in BSC arm went on to receive immunotherapy and was that adequate?
Community PollStarted
Should 1 year of adjuvant atezolizumab be the standard of care for resected Stage II-IIIA PDL1+ NSCLC?
81 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
The gold standard endpoint for trials for patients with curable NSCLC has been overall survival. If a therapy delays disease recurrence, but does not impact survival, one could argue that it should not be used in the adjuvant setting and used at the time of recurrence and similar benefits and overal...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Case Comprehensive Cancer Center
Answered on
Yes – currently adjuvant atezolizumab for 1 year following adjuvant chemotherapy should be discussed and offered as SOC for patients with PD-L1+ stage II-IIIA NSCLC. While OS remains the gold standard by which we evaluate the impact of any form of therapy in the setting of disease treated with curat...
Join for free or sign in to see the full answer